BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BioCentury | Oct 31, 2019
Product Development

Amgen deal gives BeiGene dry powder to grow its own pipeline

In its second major -- and potentially transformational -- deal with a U.S. company, BeiGene has entered a development and commercialization deal with Amgen that adds nearly two dozen compounds to the Chinese biotech’s marketed...
BC Extra | May 22, 2019
Company News

May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

Lung disease warning for Lilly breast cancer drug in Japan  Eli Lilly and Co. (NYSE:LLY) told BioCentury it has updated the Japanese label of breast cancer drug Verzenio abemaciclib to include a warning for interstitial...
BC Extra | Jan 30, 2019
Company News

Amgen's guidance comes up short, but migraine drug sales show promise

Amgen Inc. (NASDAQ:AMGN) reported 4Q18 and 2018 earnings that beat consensus estimates on Tuesday but the bellwether’s 2019 guidance fell shy of analyst expectations. The company said it expects 2019 non-GAAP EPS of $13.10-$14.30, below...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
BC Extra | Oct 25, 2018
Politics & Policy

Trump administration to peg Part B payments to international pricing

The new Trump administration proposal for Medicare Part B could dramatically decrease revenues for companies that are heavily dependent on those sales. Announced just two weeks before Election Day, the proposed changes to Medicare Part...
BC Week In Review | Sep 7, 2018
Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc. (NASDAQ:AMGN),...
BC Extra | Sep 5, 2018
Financial News

Seidenberg, Harper launch Westlake with $320M inaugural fund

Kleiner Perkins’ Beth Seidenberg launched a life science investment firm Wednesday, dubbed Westlake Village BioPartners, with $320 million in committed capital for its first fund. Sean Harper, EVP and head of R&D at Amgen Inc....
BC Extra | Jul 26, 2018
Company News

Reese succeeding Harper as Amgen EVP of R&D

Amgen Inc. (NASDAQ:AMGN) said EVP of R&D Sean Harper will retire and be succeeded by SVP of Translational Sciences and Oncology David Reese. The company also reported 2Q18 earnings on Thursday after market hours that...
Items per page:
1 - 10 of 343